Edward Walsh1, Nelson Lee2, Ian Sander3, Robert Stolper4, Jessica Zakar4, Veronique Wyffels5, David Myers6, Roman Fleischhackl7. 1. Department of Medicine University of Rochester School of Medicine and Dentistry Rochester New York USA. 2. Dalla Lana School of Public Health University of Toronto Toronto Ontario Canada. 3. University of Notre Dame Notre Dame Indiana USA. 4. IQVIA Consulting Services Cambridge Massachusetts USA. 5. Janssen-Cilag Breda The Netherlands. 6. Janssen-Cilag Solna Sweden. 7. Janssen-Cilag Vienna Austria.
Abstract
Background and Aims: The burden of respiratory syncytial virus (RSV) infection in adults is of growing concern. This study was designed to quantify disease burden, treatment approaches, and outcomes associated with RSV infections in adult subpopulations, from prehospitalization to hospital discharge. Methods: A retrospective chart analysis was conducted to collect patient-case data from hospitalized US adults (aged >18 years) with RSV infection during two RSV seasons. Patients were categorized into risk groups: comorbid lung disease, immunocompromised, older adults (aged ≥65 years), and other adults (aged <65 years). Physicians reported diagnosis, treatment choices including respiratory supportive therapy (oxygen and fluid supplementation), and outcome variables using a standardized online case form. Results: The majority (277/379; 73%) of patients presented to the emergency room, with a mean age of 60 years. Once hospitalized, the median length of stay was 6.0 days (3.0-9.0), with disease severity having the greatest impact on duration of stay. No significant between-group differences in rates of patients requiring management in intensive care units were found (comorbid lung disease, 28%; immunocompromised, 36%; older adults, 26%; and other adults, 23%). Overall, respiratory supportive therapy was the most commonly used form of treatment. Antibiotics were administered in over half of all risk groups (comorbid lung disease, 61%; immunocompromised, 59%; older adults, 59%; and other adults, 51%). Patients usually required follow-up visits following discharge, with 10%-16% requiring skilled nursing care and approximately 25% requiring assistance from a social worker. Conclusion: RSV in adult subpopulations, irrespective of age, is a significant burden to healthcare systems.
Background and Aims: The burden of respiratory syncytial virus (RSV) infection in adults is of growing concern. This study was designed to quantify disease burden, treatment approaches, and outcomes associated with RSV infections in adult subpopulations, from prehospitalization to hospital discharge. Methods: A retrospective chart analysis was conducted to collect patient-case data from hospitalized US adults (aged >18 years) with RSV infection during two RSV seasons. Patients were categorized into risk groups: comorbid lung disease, immunocompromised, older adults (aged ≥65 years), and other adults (aged <65 years). Physicians reported diagnosis, treatment choices including respiratory supportive therapy (oxygen and fluid supplementation), and outcome variables using a standardized online case form. Results: The majority (277/379; 73%) of patients presented to the emergency room, with a mean age of 60 years. Once hospitalized, the median length of stay was 6.0 days (3.0-9.0), with disease severity having the greatest impact on duration of stay. No significant between-group differences in rates of patients requiring management in intensive care units were found (comorbid lung disease, 28%; immunocompromised, 36%; older adults, 26%; and other adults, 23%). Overall, respiratory supportive therapy was the most commonly used form of treatment. Antibiotics were administered in over half of all risk groups (comorbid lung disease, 61%; immunocompromised, 59%; older adults, 59%; and other adults, 51%). Patients usually required follow-up visits following discharge, with 10%-16% requiring skilled nursing care and approximately 25% requiring assistance from a social worker. Conclusion: RSV in adult subpopulations, irrespective of age, is a significant burden to healthcare systems.
Authors: Liselotte van Asten; Cees van den Wijngaard; Wilfrid van Pelt; Jan van de Kassteele; Adam Meijer; Wim van der Hoek; Mirjam Kretzschmar; Marion Koopmans Journal: J Infect Dis Date: 2012-06-21 Impact factor: 5.226
Authors: Hong Zhou; William W Thompson; Cecile G Viboud; Corinne M Ringholz; Po-Yung Cheng; Claudia Steiner; Glen R Abedi; Larry J Anderson; Lynnette Brammer; David K Shay Journal: Clin Infect Dis Date: 2012-04-10 Impact factor: 9.079
Authors: Edward Goldstein; Sharon K Greene; Donald R Olson; William P Hanage; Marc Lipsitch Journal: Influenza Other Respir Viruses Date: 2015-09 Impact factor: 4.380
Authors: P Loubet; N Lenzi; M Valette; V Foulongne; A Krivine; N Houhou; G Lagathu; S Rogez; S Alain; X Duval; F Galtier; D Postil; P Tattevin; P Vanhems; F Carrat; B Lina; O Launay Journal: Clin Microbiol Infect Date: 2016-11-27 Impact factor: 8.067
Authors: Edward A Belongia; Jennifer P King; Burney A Kieke; Joanna Pluta; Ali Al-Hilli; Jennifer K Meece; Vivek Shinde Journal: Open Forum Infect Dis Date: 2018-11-27 Impact factor: 3.835
Authors: Ann R Falsey; Edward E Walsh; Mark T Esser; Kathryn Shoemaker; Li Yu; M Pam Griffin Journal: J Med Virol Date: 2018-09-24 Impact factor: 2.327
Authors: Edward Walsh; Nelson Lee; Ian Sander; Robert Stolper; Jessica Zakar; Veronique Wyffels; David Myers; Roman Fleischhackl Journal: Health Sci Rep Date: 2022-04-14